Crinetics Pharmaceuticals Inc
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsCrinetics Pharmaceuticals is a commercial-stage endocrine company whose first product, PALSONIFY, is approved for acromegaly, and is being acquired by Vertex for $85.00 per share.
What they do
Crinetics discovers, develops, and commercializes small-molecule therapies targeting G protein-coupled receptors for endocrine diseases and endocrine-related tumors. Its commercial product is PALSONIFY (paltusotine), an oral somatostatin receptor ligand for acromegaly. The pipeline includes atumelnant, a Phase 3 ACTH receptor antagonist for congenital adrenal hyperplasia and autonomous cortisol secretion, and CRN09682, a next-generation somatostatin receptor 2 agonist in Phase 1/2 for neuroendocrine tumors.
Revenue drivers
- PALSONIFY (paltusotine) U.S. commercial sales — Net product revenue was $24.0 million in Q2 2026, up from $10.3 million in Q1 2026, with 245 enrollment forms received in the quarter and over 70% of treated patients on reimbursed therapy.
- Collaborative revenue from SKK License — Exclusive right to commercialize paltusotine in Japan granted to SKK; collaboration revenue was $1.0 million in Q2 2026, compared to $1.0 million in the same period of 2025.
- Future international sales — CHMP positive opinion for PALSONIFY in acromegaly; potential European Commission decision in H1 2026, which could open EU sales.
Recent performance
For Q2 2026, total revenue was $25.1 million, including $24.0 million in PALSONIFY net product revenue, up from $1.0 million in Q2 2025. Net loss was $120.9 million for the quarter, versus $115.6 million in the prior-year quarter. R&D expenses were $99.9 million and SG&A was $57.6 million. Cash, cash equivalents, and investments totaled $1.2 billion as of June 30, 2026. The company reported 385 unique HCPs had prescribed PALSONIFY within the first three quarters of launch.
Strategy
The company is executing a U.S. commercial launch of PALSONIFY, educating HCPs and patients, and engaging payers to secure formulary access. It is advancing late-stage pipeline programs, including Phase 3 CALM-CAH and BALANCE-CAH for atumelnant in CAH, and planned Phase 2/3 EQUILIBRIUM-ADCS. It is also building infrastructure for EU commercialization if approved. On July 6, 2026, Crinetics agreed to be acquired by Vertex for $85.00 per share in cash, with the deal expected to close in Q3 2026.
Risks
- Acquisition may not close — The Vertex transaction is subject to regulatory approvals, stockholder approval, and other conditions; failure to close could disrupt operations and adversely affect the stock price.
- Commercial execution risk — PALSONIFY launch is early; broader and sustained market acceptance, payer coverage, and competition are unproven.
- Clinical and regulatory setbacks — Phase 3 trials for atumelnant (CALM-CAH, BALANCE-CAH) and other programs could fail or be delayed, affecting future growth.
- Substantial ongoing losses — The company has incurred significant net losses and negative operating cash flow since inception and expects to continue incurring losses, requiring additional financing if the acquisition does not close.
Outlook
Management withdrew financial guidance and suspended its earnings call due to the pending Vertex acquisition. The transaction is expected to close in Q3 2026, subject to closing conditions. If the deal closes, the company will be integrated into Vertex; if it does not, the company expects to continue commercializing PALSONIFY and advancing its pipeline.